Stem Cell Therapy for
Myocardial Infarction
in Costa Rica
Stem cell therapy for myocardial infarction in Costa Rica offers a promising regenerative approach for patients recovering from heart attack. At Stem Cells Bio Clinic, we provide advanced, personalized treatment designed to support cardiac repair, improve heart function, and enhance long-term recovery — especially for international patients seeking affordable care.
Cardiac Repair Matrix
Targeted Myocardial Regeneration
Stem cell therapy aims to support the repair of damaged heart tissue following a heart attack, improve cardiac function, and promote long-term recovery — offering new possibilities for patients affected by myocardial infarction.
Advanced Regenerative Treatment for Heart Attack Recovery
Stem cell therapy for myocardial infarction in Costa Rica is an emerging solution for patients seeking advanced, non-surgical options to support heart recovery after a cardiac event. A heart attack can permanently damage the heart muscle, reducing its ability to pump blood effectively and impacting overall health and quality of life.
While conventional treatments such as medications, stents, and bypass surgery are essential for stabilizing patients, they do not repair damaged cardiac tissue. This is where regenerative medicine for heart disease offers a new approach focusing on healing, not just symptom management.
At Stem Cells Bio Clinic, we provide personalized stem cell therapy for heart attack recovery, helping both local and international patients access safe, affordable, and evidence-based treatment in Costa Rica.
What is Myocardial Infarction?
A myocardial infarction (heart attack) occurs when a blockage in the coronary arteries prevents oxygen-rich blood from reaching part of the heart muscle. Without oxygen, heart cells begin to die within minutes, leading to permanent tissue damage.
This damage often results in:
- Reduced cardiac output (weakened pumping ability)
- Scar tissue formation in the heart
- Decreased physical endurance
- Increased risk of heart failure
Symptoms of Myocardial Infarction
The symptoms of myocardial infarction can vary in intensity but often appear suddenly and require immediate medical attention. Early recognition is critical for preventing severe complications. Common symptoms include:
- Unusual fatigue
- Nausea or vomiting
- General weakness or dizziness
- Irregular or abnormal heartbeat
- Excessive sweating (cold sweats)
- Anxiety or a feeling of impending doom
- Shortness of breath or difficulty breathing
- Severe chest pain or pressure that may radiate to the left arm, shoulder, neck, or jaw
Two Paths to Heart Attack Recovery
Conventional care stabilizes the heart. Regenerative therapy aims to repair it.
Treatments for Myocardial Infarction
Treatment focuses on restoring blood flow, minimizing heart damage, and preventing complications.
Standard treatments include
- Aspirin and blood thinners
- Thrombolytic therapy (clot-dissolving drugs)
- Heparin and anticoagulants
- Nitroglycerin (improves blood flow)
- Beta-blockers (reduce heart workload)
In some cases
- Coronary angioplasty and stenting
- Coronary artery bypass surgery (CABG)
Life-saving, but does not repair damaged heart tissue.
Stem Cell Therapy for Myocardial Infarction
Focuses on supporting the body’s natural healing process and improving cardiac function after a heart attack — using mesenchymal stem cells (MSCs) to release growth factors that promote repair in damaged tissue.
How stem cell therapy may help
- Supports repair of damaged heart muscle tissue
- Reduces inflammation in the cardiac environment
- Promotes formation of new blood vessels (angiogenesis)
- Helps improve circulation and oxygen supply
- May enhance overall heart function and patient outcomes
Unlike conventional treatments, cardiac stem cell therapy targets the underlying damage rather than only managing symptoms.
Benefits of Stem Cell Therapy for Heart Attack Recovery
Patients exploring stem cell therapy for myocardial infarction in Costa Rica are often looking for safer alternatives to invasive procedures.
Minimally Invasive
No major surgery required for treatment delivery
Improved Heart Function
May improve ejection fraction and pumping ability
Tissue Repair Support
Supports repair of damaged cardiac tissue
Symptom Relief
Reduces symptoms like fatigue and shortness of breath
Better Quality of Life
Improves overall day-to-day wellbeing
May Delay Surgery
May reduce or delay the need for surgical intervention
Why Choose Costa Rica for Stem Cell Therapy?
Costa Rica has become a preferred destination for medical tourism and regenerative medicine due to its combination of quality care and affordability.
Patients from across the U.S. and internationally choose Costa Rica for affordable stem cell therapy for heart disease without compromising on quality.
Scientific References:
Hodgson, D.M., Behfar, A., Zingman, L.V., Kane, G.C., Perez-Terzic, C., Alekseev, A.E., Pucéat, M., and Terzic, A. 01 Aug 2004. https://doi.org/10.1152/ajpheart.01247.2003
He, Y.C., Yuan, G.D., Li, N., Ren, M.F., Zhang, Q., Deng, K.N., Wang, L.C., Xiao, W.L., Ma, N., Stamm, C., Felthaus, O., Prantl, L., Nie, J., Wang, G. Recent advances in mesenchymal stem cell therapy for myocardial infarction. Clinical Hemorheology and Microcirculation, 10.3233/CH-249101, (1-16), (2024).
Sun R. Advances in stem cell therapy for cardiovascular disease (Review). National Journal of Mol. Med. 38: 23-29, 2016.
Hou, L. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am J Physiol Heart Circ Physiol 310: H455–H465, 2016.
Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308: 2369–2379, 2012.